American Acquisition Opportunity Inc
Change company Symbol lookup
Select an option...
AMAOU American Acquisition Opportunity Inc
VTI Vanguard Total Stock Market Index Fund ETF Shares
DSEY Diversey Holdings Ltd
LGIH LGI Homes Inc
CRZNU Corazon Capital V838 Monoceros Corp
PCG-I Pacific Gas and Electric Co
ASZ Austerlitz Acquisition II Corp
$NQEG60CAD Nasdaq Egypt Energy Price Return CAD
PLXS Plexus Corp
LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc
Go

Company profile

American Acquisition Opportunity Inc. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It has not selected any specific business combination target and has not engaged in any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search for prospects within the land and resource holding company industry. The Company neither engages in any business operations nor generates any revenues.

Closing Price
$10.17
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
1

10-day average volume:
366
1

Moderna says it has about $15 billion in cash, working on combined COVID/seasonal flu booster

7:27 am ET September 9, 2021 (MarketWatch)
Print

Moderna Inc. (MRNA) said Thursday it had a cash position of about $15 billion as of Aug. 31. The company made the disclosure as it offered an update on its line of product candidates based on mRNA technology, that includes a vaccine against COVID-19, the first Moderna product to win authorization from the U.S. Food and Drug Administration. In a statement released ahead of an R&D day, the company highlighted a new product candidate that would combine a COVID-19 booster with a seasonal flu booster vaccine. The company recently submitted an application to the FDA for approval of its COVID booster shot, and said it saw "robust antibody responses" in a Phase 2 study. Overall, the company has 37 programs in development across 34 development candidates, including 22 in current clinical studies. Shares were flat premarket, but have gained 305% in the year to date, while the SPDR S&P Biotech ETF (XBI) has fallen 6% and the S&P 500 has gained 20%.

-Ciara Linnane

	

(END) Dow Jones Newswires

September 09, 2021 07:27 ET (11:27 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.